Salvianolic acid B alleviated myocardial ischemia-reperfusion injury via modulating SIRT3-mediated crosstalk between

Xiao-Hong Wei1, Jie Chen1, Xue-Fen Wu1

  • 1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Hutong, Dongcheng District, Beijing, 100700, China.

Abstract

Insights

Salvianolic acid B protects against myocardial ischemia-reperfusion injury (MIRI) by targeting SIRT3, which regulates mitochondrial ROS and NLRP3 inflammasome activation. This study reveals a novel therapeutic approach for MIRI treatment.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Medicine
  • Inflammation Research

Background:

  • Mitochondrial reactive oxygen species (mtROS) and NLRP3 inflammasome activation are key in myocardial ischemia-reperfusion injury (MIRI).
  • The upstream regulation and interaction of mtROS and NLRP3 in MIRI remain unclear.

Purpose of the Study:

  • To investigate the therapeutic effect of Salvianolic acid B (Sal B) on MIRI.
  • To elucidate the molecular mechanism of Sal B, focusing on the role of SIRT3.

Main Methods:

  • Utilized rat MIRI and H9c2 cell hypoxia/reoxygenation models with SIRT3 knockdown/overexpression.
  • Assessed protein expression (Western blot, immunofluorescence), mtROS levels (MitoSOX™ Red), and inflammatory markers (ELISA).
  • Investigated Sal B-SIRT3 interaction using biolayer interferometry, cellular thermal shift assay, and molecular docking.

Main Results:

  • SIRT3 deficiency exacerbated MIRI by increasing MnSOD acetylation, mtROS, and NLRP3 inflammasome activation.
  • SIRT3 overexpression conferred protection by inhibiting these pathways.
  • Sal B treatment upregulated SIRT3, reduced mtROS and NLRP3 activation, decreased infarct size, and improved myocardial morphology.
  • The protective effects of Sal B were abolished by a SIRT3 inhibitor.

Conclusions:

  • SIRT3 critically mediates the interplay between mtROS and NLRP3 inflammasome in MIRI pathogenesis.
  • Sal B demonstrates therapeutic potential for MIRI by targeting the SIRT3 pathway.

Related Concept Videos